A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif

Chemical Research in Toxicology

Volumn 20, Issue 12, 2007, Pages 1954-1965

  Kalgutkar, Amit S ^a   Driscoll, James ^a   Zhao, Sabrina X ^a   Walker, Gregory S ^a   Shepard, Richard M ^a   Soglia, John R ^a   Atherton, James ^a   Yu, Linning ^a   Mutlib, Abdul E ^a   Munchhof, Michael J ^a   Reiter, Lawrence A ^a   Jones, Christopher S ^a   Doty, Johnathan L ^a   Trevena, Kristen A ^a   Shaffer, Christopher L ^a   Ripp, Sharon L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 CHLORO 5 [[4 [4 FLUORO 3 (TRIFLUOROMETHYL)PHENYL]THIAZOL 2 YL]CARBAMOYL]PYRIDINE 2 YL]PIPERIDINE 4 CARBOXYLIC ACID; 1,2,4 THIADIAZOLE DERIVATIVE; 4 [4 FLUORO 3 (TRIFLUOROMETHYL)PHENYL]THIAZOL 2 AMINE; AMINOTHIADIAZOLE; CARBOXYLIC ACID DERIVATIVE; CYTOCHROME P450; GLUTATHIONE; GLYOXAL DERIVATIVE; HYDROXYLAMINE; PIPERIDINE DERIVATIVE; THIAZOLE DERIVATIVE; THIOUREA DERIVATIVE; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; EPOXIDATION; HUMAN; HUMAN CELL; HYDROLYSIS; LIVER CELL; LIVER MICROSOME; MALE; MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CELL LINE; DRUG STABILITY; GLUTATHIONE; HEPATOCYTES; HUMANS; MALE; MICE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, THROMBOPOIETIN; THIAZOLES; TRANSFECTION;

EID: 38149063929     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx700270r     Document Type: Article

References (52)

1. Kaushansky, K. (2005) The molecular mechanisms that control thrombopoiesis. J. Clin. Invest. 115, 3339-3347.
2. Solberg, L. A., Jr. (2005) Biologic aspects of thrombopoietins and the development of therapeutic agents. Curr. Hematol. Rep. 4, 423-428.
3. Drachmen, J. G., Sabath, D. F., Fox, N. E., and Kaushansky, K. (1997) Thrombopoietin signal transduction in purified murine megakaryocytes. Blood 89, 483-492.
4. Ezumi, Y., Takayama, H., and Okuma, M. (1995) Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett. 374, 48-52.
5. Rojnuckarin, P., Drachman, J. G., and Kaushansky, K. (1999) Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood 94, 1273-1282.
6. de Sauvage, F. J., Hass, P. E., Spencer, S. D., Malloy, B. E., Gurney, A. L., Spencer, S. A., Darbonne, W. C., Henzel, W. J., Wong, S. C., Kuang, W. J., Oles, K. J., Hultgren, B., Jr., Goeddel, D. V., and Eaton, D. L. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369, 533-538.
7. Foster, D. C., Sprecher, C. A., Grant, F. J., Kramer, J. M., Kuuper, J. L., Holly, R. D., Whitmore, T. E., Heipel, M. D., Bell, L. A., Ching, A. F. T., McGrane, V., Hart, C., O'Hara, P. J., and Lok, S. (1994) Human thrombopoietin: Gene structure, cDNA sequence, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U.S.A. 91, 130223-130227.
8. Kaushansky, K., Lok, S., Holly, R. D., Broudy, V. C., Lin, N., Bailey, M. C., Forstrom, J. W., Buddle, M. M., Oort, P. J., Hagen, F. S., Roth, G. J., Papayannopoulou, T., and Foster, D. C. (1994) Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369, 568-571.
9. Lok, S., Kaushansky, K., Holly, R. D., Kuijper, J. L., Lofton-Day, C. E., Oort, P. J., Grant, F. J., Heipel, M. D., Burkhead, S. K., Kramer, J. M., Bell, L. A., Sprecher, C. A., Blumberg, H., Johnson, R., Prunkard, D., Ching, A. F. T., Mathewes, S. L., Bailey, M. C., Forstrom, J. W., Buddle, M. M., Osborn, S. G., Evans, S. J., Sheppard, P. O., Presnell, S. R., O'Hara, P. J., Hagen, F. S., Roth, G. J., and Foster, D. C. (1994) Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 369, 565-568.
10. Nash, R. A., Kurzrock, R., DiPersio, J., Linker, C., Maharaj, D., Nademanee, A. P., Negrin, R., Nimer, S., Shulman, H., Ashby, M., Jones, D., Appelbaum, F. R., and Champlin, R. (2000) A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 6, 25-34.
11. Safonov, I. G., Heerding, D. A., Keenan, R. M., Price, A. T., Erickson-Miller, C. L., Hopson, C. B., Levin, J. L., Lord, K. A., and Tapley, P. M. (2006) New benzimidazoles as thrombopoietin receptor agonists. Bioorg. Med. Chem. Lett. 16, 1212-1216.
12. Duffy, K. J., Price, A. T., Delorme, E., Dillon, S. B., Duquenne, C., Erickson-Miller, C., Giampa, L., Huang, Y., Keenan, R. M., Lamb, P., Liu, N., Miller, S. G., Rosen, J., Shaw, A. N., Smith, H., Wiggall, K. J., Zhang, L., and Luengo, J. I. (2002) Identification of a pharmacophore for thrombopoietic activity of small, non-peptidyl molecules. 2. Rational design of naphtho[1,2-d]imidazole thrombopoietin mimics. J. Med. Chem. 45, 3576-3578.
13. Duffy, K. J., Darcy, M. G., Delorme, E., Dillon, S. B., Eppley, D. F., Erickson-Miller, C., Giampa, L., Hopson, C. B., Huang, Y., Keenan, R. M., Lamb, P., Leong, L., Liu, N., Miller, S. G., Price, A. T., Rosen, J., Shah, R., Shaw, T. N., Smith, H., Stark, K. C., Tian, S. S., Tyree, C., Wiggall, K. J., Zhang, L., and Luengo, J. I. (2001) Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis. J. Med. Chem. 44, 3730-3745.
14. Kimura, T., Kaburaki, H., Tsujino, T., Ikeda, Y., Kato, H., and Watanabe, Y. (1998) A non-peptide compound which can mimic the effect of thrombopoietin via c-Mpl. FEBS Lett. 428, 250-254.
15. Munchhof, M. J., Abramov, Y. A., Antipas, A. S., Blumberg, L. C., Brissette, W. H., Brown, M. F., Casavant, J. M., Doty, J. L., Driscoll, J., Harris, T. M., Wolf-Gouveia, L. A., Jones, C. S., Li, Q., Linde, R. G., Lira, P. D., Marfat, A., McElroy, E., Mitten-Fry, M., McCurdy, S. P., Reiter, R. A., Ripp, S. L., Shavnya, A., Shepard, R. M., Smeets, M. I., Sperger, D., Thomasco, L. M., Trevena, K. A., Zhang, F., and Zhang, L. (2007) The Identification of Orally Bioavailable Thrombopoietin Agonists. Bioorg. Med. Chem. Lett., in press.
16. Kalgutkar, A. S., Gardner, I., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D. K., Lee, J. S., Nakai, Y., O'Donnell, J. P., Boer, J., and Harriman, S. P. (2005) A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6, 161-225.
17. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
18. Ju, C., and Uetrecht, J. P. (2002) Mechanism of idiosyncratic drug reactions: reactive metabolite formation, protein binding and the regulation of the immune system. Curr. Drug Metab. 3, 367-377.
19. Dalvie, D. K., Kalgutkar, A. S., Khojasteh-Bakht, S. C., Obach, R. S., and O'Donnell, J. P. (2002) Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem. Res. Toxicol. 15, 269-299.
20. Mizutani, T., Yoshida, K., and Kawazoe, S. (1994) Formation of toxic metabolites from thiabendazole and other thiazoles in mice. Identification of thioamides as ring cleavage products. Drug Metab. Dispos. 22, 750-755.
21. Mizutani, T., and Suzuki, K. (1996) Relative hepatotoxicity of 2-(substituted phenyl)thiazoles and substituted thiobenzamides in mice: evidence for the involvement of thiobenzamides as ring cleavage metabolites in the hepatotoxicity of 2-phenylthiazoles. Toxicol. Lett. 85, 101-105.
22. Stevens, G. J., Hitchcock, K., Wang, Y. K., Coppola, G. M., Versace, R. W., Chin, J. A., Shapiro, M., Suwanrumpha, S., and Mangold, B. L. (1997) In vitro metabolism of N-(5-chloro-2-methylphenyl)-N′-(2- methylpropyl)thiourea: species comparison and identification of a novel thiocarbamide-glutathione adduct. Chem. Res. Toxicol. 10, 733-741.
23. Kedderis, G. L., and Miwa, G. T. (1988) The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab. Rev. 19, 33-62.
24. Lakshmi, V. M., Zenser, T. V., Sohani, S., and Davis, B. B. (1992) Mechanism of formation of the thioether conjugate of the bladder carcinogen 2-amino-4-(5-nitro-2-furyl)-thiazole (ANFT). Carcinogenesis 13, 2087-2093.
25. Lakshmi, V. M., Mattammal, M. B., Zenser, T. V., and Davis, B. B. (1990) Mechanism of peroxidative activation of the bladder carcinogen 2-ammo-4-(5-nitro-2-furyl)-thiazole (ANFT): comparison with benzidine. Carcinogenesis 11, 1965-1970.
26. Blumberg, L. C., Brown, M. F., Munchhof, M. J., and Reiter, L. A. (2007) Aminothiazole derivatives as agonists of the thrombopoietin receptor. WO2007004038 A1.
27. Blumberg, L. C., Brown, M. F., Munchhof, M. J., and Reiter, L. A. (2007) Aminothiazole derivatives as agonists of the thrombopoietin receptor. WO2007036769 A1.
28. Paul, S., Gupta, M., and Loupy, A. (2002) Microwave assisted synthesis of 1,5-disubstituted hydantoins and thiohydantoins in solvent-free conditions. Synthesis 1, 75-78.
29. Xu, X., Yang, Z., Chen, G., and Qian, X. (2003) A facile synthesis of substituted N-benzoylthiourea. Synth. Commun. 33, 2585-2592.
30. Benet, L. Z., and Galeazzi, R. L. (1971) Noncompartmental determination of the steady-state volume of distribution. J. Pharm. Sci. 68, 1071-1074.
31. Baillie, T. A., and Davis, M. R. (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319-325.
32. Kulanthaivel, P., Barbuch, R. J., Davidson, R. S., Yi, P., Rener, G. A., Mattiuz, E. L., Hadden, C. E., Goodwin, L. A., and Ehlhardt, W. J. (2004) Selective reduction of N-oxides to amines: application to drug metabolism. Drug Metab. Dispos. 32, 966-972.
33. Thomas, R. C., and Harpootlian, H. (1975) Metabolism of minoxidil, a new hypotensive agent II: biotransformation following oral administration to rats, dogs, and monkeys. J. Pharm. Sci. 64, 1366-1371.
34. Nelson, S. D., Nelson, W. L., and Trager, W. F. (1978) N-Hydroxyamide metabolites of lidocaine. Synthesis, characterization, quantitation, and mutagenic potential. J. Med. Chem. 21, 721-725.
35. Zlokarnik, G., Negulescu, P. A., Knapp, T. E., Mere, L., Burres, N., Feng, L., Whitney, M., Roemer, K., and Tsien, R. Y. (1998) Quantitation of transcription and clonal selection of single living cells with β-lactamase as reporter. Science 279, 84-88.
36. Hobbs, D. C., and Twomey, T. M. (1977) Metabolism of sudoxicam by the rat, dog, and monkey. Drug Metab. Dispos. 5, 75-81.
37. Rainsford, K. D. (2004) Pharmacology and toxicology of COX-2 inhibitors. In COX-2 Inhibitors/Milestones in Drug Therapy (Pairet, M., and van Ryn, J., Eds.) pp 67-132, Birkhauser, Basel, Switzerland.
38. Chesne, C., Guyomard, C., Guillouzo, A., Schmid, J., Ludwig, E., and Sauter, T. (1998) Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 28, 1-13.
39. Hobbs, D. C., and Twomey, T. M. (1981) Metabolism of Piroxicam by laboratory animals. Drug Metab. Dispos. 9, 114-118.
40. Voogd, C. E., van der Stel, J. J., and Verharen, H. W. (1983) The capacity of some nitro- and amino-heterocyclic sulfur compounds to induce base-pair substitutions. Mutat. Res. 118, 153-165.
41. Rice, J. R., Zenser, T. V., and Davis, B. B. (1985) Formation of thioether conjugates of the bladder carcinogen ANFT catalyzed by prostaglandin synthase. Carcinogenesis 6, 585-590.
42. Musah, R. A., and Goodin, D. B. (1997) Introduction of novel substrate oxidation into cytochrome c peroxidase by cavity complementation: oxidation of 2-aminothiazole and covalent modification of the enzyme. Biochemistry 36, 11665-11674.
43. Bessems, J. G. M., de Groot, M. J., Baede, J. M., te Koppele, J. M., and Vermeulen, N. P. E. (1998) Hydrogen atom abstraction of 3,5-disubstituted analogues of paracetamol by horseradish peroxidase and cytochrome P450. Xenobiotica 28, 855-875.
44. Kassahun, K., Skordos, K., McIntosh, I., Slaughter, D., Doss, G. A., Baillie, T. A., and Yost, G. S. (2005) Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic α,β-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem. Res. Toxicol. 18, 1427-1437.
45. Yang, X., and Chen, W. (2005) In vitro microsomal metabolic studies on a selective mGluR5 antagonist MTEP: characterization of in vitro metabolites and identification of a novel thiazole ring opening aldehyde metabolite. Xenobiotica 35, 797-809.
46. Offen, C. P., Frearson, M. J., Wilson, K., and Burnett, D. (1985) 4,5-Dimethylthiazole-N-oxide-S-oxide: a metabolite of chlormethiazole in man. Xenobiotica 15, 503-511.
47. Testa, B., and Mayer, J. M. (2003) The hydrolysis of amides. In Hydrolysis in Drug and Prodrug Metabolism (Chemistry, Biochemistry, and Enzymology) (Testa, B., and Mayer, J. M., Eds.) Chapter 4, pp 81-162, VHCA, Zürich.
48. Spahn-Langguth, H., and Benet, L. Z. (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab. Rev. 24, 5-47.
49. Shipkova, M., Armstrong, V. W., Oellerich, M., and Wieland, E. (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 25, 1-16.
50. Benet, L. Z., Spahn-Langguth, H., Iwakawa, S., Volland, C., Mizuma, T., Mayer, S., Mutschler, E., and Lin, E. T. (1993) Predictability of the covalent binding of acidic drugs in man. Life Sci. 53, PL141-PL146.
51. Bolze, S., Bromet, N., Gay-Feutry, C., Massiere, F., Boulieu, R., and Hulot, T. (2002) Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin. Drug Metab. Dispos. 30, 404-413.
52. Castillo, M., and Smith, P. C. (1995) Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab. Dispos. 23, 566-572.